Source: The San Diego Union Tribune

Takedaventures: San Diego biotech snags $137M for precision attack on cancer

VelosBio's experimental drug works a bit like a Trojan Horse, slipping inside cancer cells before destroying them

Read full article »

Takedaventures's Competitors | Takedaventures's News | Takedaventures's Financials

Followers on Owler

Est. Annual Revenue

$5.0-25M

Est. Employees

1-25

CEO

Graeme Martin

CEO Approval Rating

70/100

TVI builds a portfolio of strategic investments with an immediate emphasis on cardiometabolic, central nervous system and oncology therapeutic domain.